Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China , July 25, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical…
